Navigation Links
WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
Date:12/18/2007

- Rawson to Oversee Scientific Integrity of WellGen Programs and Advance

Collaborations with Food and Beverage Industry Leaders -

NORTH BRUNSWICK, N.J., Dec. 18 /PRNewswire/ -- WellGen, Inc., a biotechnology company using nutrigenomics to discover and develop food ingredients for wellness products, today announced the appointment of Nancy E. Rawson, M.Sc., Ph.D., as Chief Scientific Officer. Dr. Rawson fills a newly created position that will report directly to the CEO.

Dr. Rawson, 51, joins WellGen at a critical stage in its development, as the Company has just brought its first functional food ingredient product to market and is conducting human studies for its second, while seeking to significantly expand the number of ingredients in its pipeline. In addition, the Company is completing the installation of a new, state-of-the-art molecular biology and natural products chemistry laboratory.

Dr. Rawson comes to WellGen with an extensive background in food, nutrition and basic biomedical research. Dr. Rawson most recently worked at the Monell Chemical Senses Center in Philadelphia, PA, as an Associate Member. The Monell Center is an independent scientific institute dedicated to basic research on the senses of taste, smell and chemosensory irritation. During her tenure there, Dr. Rawson built relationships with well-recognized leaders in the food and beverage industry as well as with researchers throughout the world.

Previously, Dr. Rawson was a Senior Nutrition Research Associate at the Campbell Soup Company. She also has held numerous advisory and university teaching positions.

Dr. Kathleen Mullinix, Chief Executive Officer of WellGen, said, "We are fortunate to have Nancy Rawson, who is an outstanding scientist, join our company, and we look to her to ensure that our products' scientific foundations will meet the very highest standards. Her background in both research and industry will also enable her to be an effective leader in working with partner companies to bring new functional foods and beverages to market."

Richard Morgan, CEO of Amphion Innovations plc (LSE: AMP), a leading investor in WellGen, said, "Nancy Rawson has an excellent reputation in the food industry and an exceptional track record of scientific accomplishments. These will help WellGen continue to establish its leading position in the growing functional foods and beverages industry."

During her career, Dr. Rawson has received numerous honors and awards in bioscience and nutrition, and has often been quoted in the media as an authority in these fields. She is a frequent lecturer and conference panelist, and has authored and collaborated on a wide range of publications for both academic and non-technical audiences. She graduated with a Bachelor of Science degree from Fairfield University, Fairfield, CT, earned a Masters of Science in Nutrition from the University of Massachusetts, Amherst, and received a Ph.D. in Biology from the University of Pennsylvania.

About Amphion Innovations plc

Amphion Innovations plc (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors. Amphion uses a focused, hands-on company building approach based on decades of experience in both the US and UK. On the web: http://www.amphionplc.com

About WellGen

WellGen, Inc., based in North Brunswick, NJ, is a biotechnology company that is discovering and developing products for food, therapeutics, and dietary supplement markets with a strategic focus on functional foods. WellGen's proprietary technology platform is a method of screening the effect of food and related substances on the expression of genes associated with human health conditions. The company has developed proprietary substances that help maintain health and reduce risk and severity for a variety of diseases. Please visit our website at http://www.wellgen.com for more information.


'/>"/>
SOURCE WellGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. KGI Names Kerry Howell Vice President for Advancement
2. Vical Names Andrew de Guttadauro Vice President, Corporate Development
3. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
4. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
5. CryoLife Names Philip Theodore as Vice President, General Counsel
6. Genstar Names Michael Hurt to Its Strategic Advisory Board
7. PPD Names Daniel Darazsdi as Chief Financial Officer
8. Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year
9. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
10. Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer
11. Osprey Pharmaceuticals Names Jack M. Anthony as CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search ... in its continued commitment to the advancement of the clinical trials segment. Hosted ... related to clinical trial planning and management. , As executive talent specialists ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... paralysis, today announced that it has submitted a 510(k) to the FDA, requesting ... utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The submission marks ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... the latest paper by its Science Editor, Dr. Elisabeth Bik, in the December ... Microbiologie). Dr. Bik joined uBiome in October 2016 from her previous position at ...
(Date:1/18/2017)...  Caris Life Sciences, a leading innovator in ... private funder of pancreatic cancer research, are collaborating ... of immunotherapy in the treatment of pancreatic cancer. ... identify potential trial candidates based on biomarker expression ... study investigators. The Lustgarten Foundation is a sponsor ...
Breaking Biology Technology:
(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
(Date:1/11/2017)... Johnson, co-founder of Visikol Inc. a company originally funded with an ... the elite "Forbes 30 Under 30" list in the Science category. ... fields nationwide to be recognized as a leader in business and ... ... PhD candidate at Rutgers University. Visikol , ...
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at this ... leader in connected health and biometric measurement devices and services, will be ... On display in A&D Medical,s special CES Exhibit Suite , ... ongoing expansion of the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):